Form 8-K NPS PHARMACEUTICALS INC For: Nov 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Canaccord Keeps NPS Pharma (NPSP) at 'Buy'; Some Centers Slower to Put Patients on Gattex
November 11, 2014 11:07 AM ESTCanaccord Genuity affirms NPS Pharmaceuticals (Nasdaq: NPSP) at Buy with a price target of $42 following Q3 results reported Monday night.
Analyst John Newman noted that Gattex growth of about 18.6 percent over Q2 was flat with expectations, but guidance of $100 to... More
NPS Pharmaceuticals (NPSP) Misses Q3 EPS by 3c
November 10, 2014 4:07 PM ESTNPS Pharmaceuticals (NASDAQ: NPSP) reported Q3 EPS of ($0.02), $0.03 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $57.2 million versus the consensus estimate of $59.5 million.
For earnings history and earnings-related data on NPS Pharmaceuticals (NPSP) click here.
... More